{"commentary":{"count":6,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":5,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"PIVOT-10","nct_id":"NCT03785925","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pivot-10-nct03785925. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"PIVOT-10","arms":[{"description":"Participants will receive bempegaldesleukin (NKTR-214) in combination with nivolumab.","label":"Combination of bempegaldesleukin (NKTR-214) + nivolumab","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2022-06-30","type":"ACTUAL"},"conditions":["Urinary Bladder Neoplasm","Neoplasm Metastasis"],"enrollment":{"count":192,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Bempegaldesleukin","type":"BIOLOGICAL"},{"name":"Nivolumab","type":"BIOLOGICAL"}],"last_update":"2023-03-28","lead_sponsor":"Nektar Therapeutics","official_title":"A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-02-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have Low Programmed Cell Death Ligand (PD-L1) Expression","timeFrame":"Tumor assessments were performed at baseline and every 9 weeks from Cycle 1 Day 1 for the first 12 months, and then every 12 weeks as indicated in the Schedule of Events, up to approximately 27 months"}],"references":[],"start_date":{"date":"2019-04-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer","url":"https://clinicaltrials.gov/study/NCT03785925"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pivot-10-nct03785925"}